Grifols, S.A. recently announced that in 2017, the company donated over 25 million international units (IU) of factor products used to treat hemophilia A and B. According to a recent press release, the donation is part of Grifols’ commitment to provide a minimum of 200 million IU of factor to the World Federation of Hemophilia (WFH) Humanitarian Aid Program over a span of eight years – Grifols began this commitment in 2014. The company expects to make an additional donation of nearly 25 million IUs in 2018.
The announcement was made to coincide with World Hemophilia Day on April 17th. “On World Hemophilia Day, we celebrate our long-standing commitment to the bleeding disorders community,” said Victor Grifols Deu, Co-CEO of Grifols. “Grifols is dedicated to supporting the mission of the WFH and we share the common goal of helping to ensure life-changing treatments reach patients who have little or no access to care.”
In much of the developing world, access to life-saving factor therapies is either extremely limited or nonexistent. The WFH Humanitarian Aid Program is designed to ameliorate the effects of such a shortfall.
“The commitment that Grifols has made to the WFH Humanitarian Aid Program ensures access to treatment for many in need,” said Alain Bauman, CEO, WFH, and Executive Director of WFH USA. “We are grateful for this continued support, helping us work towards our global mission.”
Source: PRNewswire, April 16, 2018
